Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes
Clinical Kidney Journal · 01.10.2026 · 19 (10)
DOI: 10.1093/ckj/sfag326 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 14.09.2026. Verfasst von Shuo Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Labor…. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, CAMS, Peking Union Medical College Hospital.
Abstract (Originalsprache)
Background
Idiopathic multicentric Castleman disease–thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly syndrome (iMCD-TAFRO) is a clinically aggressive subtype. Renal involvement and its impact on prognosis are poorly characterized. We aimed to describe renal clinicopathological features and outcomes in a large iMCD-TAFRO cohort.
Methods
This 10-year retrospective cohort study enrolled iMCD-TAFRO patients at Peking Union Medical College Hospital. Renal involvement was defined by iMCD consensus criteria. Survival was analyzed using Kaplan–Meier methods.
Results
A total of 48 patients (70.8% male; mean age 45 ± 15 years) were included. Renal involvement was observed in 95.8% (46/48) of the patients, presenting predominantly with reduced urine output, mild hematuria and proteinuria, as well as elevated serum creatinine. Acute kidney injury (AKI) occurred in 80.4% (37/46) of patients showing renal involvement and 37.8% of them required renal replacement therapy. Renal biopsies (n = 7) revealed glomerular microangiopathy in six cases. AKI was associated with elevated C-reactive protein (CRP) and D-dimer levels, and CRP levels correlated with peak serum creatinine levels. Therapy targeting the iMCD was mainly bortezomib, cyclophosphamide and dexamethasone regimen (31/48, 64.6%) with/without anti-interleukin-6 therapy. Nine patients died within hospital or during follow-up. Among AKI patients, 28/37 (75.7%) showed full recovery of renal function. Despite worse renal function at baseline, no significant survival difference was observed between dialyzed and non-dialyzed patients.
Conclusions
Renal involvement in iMCD-TAFRO is common and frequently manifests as AKI associated with systemic inflammation. Early and aggressive therapy combined with supportive renal care, including timely dialysis, improved renal recovery and overall prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Molecular Pathology Diagnosis and Translational Research on R…
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing,China.
ORCID-Profile: Shuo Zhang, Fei Teng, Jian Li, Limeng Chen
Förderung
- National Key Research and Development Program of China
- CAMS
- Peking Union Medical College Hospital
Zitieren
APA
Zhang, S., Liu, H., Li, S., Wen, Y., Ye, W., Ye, W., Zheng, H., Xu, L., Teng, F., Wang, Y., Zheng, K., Xia, P., Zhang, L., Li, J., Li, X., & Chen, L. (2026). Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes. Clinical Kidney Journal, 19(10). https://doi.org/10.1093/ckj/sfag326
Vancouver
Zhang S, Liu H, Li S, Wen Y, Ye W, Ye W, et al. Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes. Clinical Kidney Journal. 2026;19(10). doi:10.1093/ckj/sfag326
BibTeX
@article{Zhang2026,
author = {Zhang, Shuo and Liu, Hanshu and Li, Siyuan and Wen, Yubing and Ye, Wenling and Ye, Wei and Zheng, Hua and Xu, Lubin and Teng, Fei and Wang, Ying and Zheng, Ke and Xia, Peng and Zhang, Lu and Li, Jian and Li, Xuemei and Chen, Limeng},
title = {Kidney involvement in idiopathic multicentric Castleman disease–TAFRO syndrome: clinical spectrum, pathology and outcomes},
journal = {Clinical Kidney Journal},
year = {2026},
volume = {19},
number = {10},
doi = {10.1093/ckj/sfag326}
}
EUVIMED